Itoco Inc. (ITMC)
USD 0.01
(177.78%)
USD 0.01
(177.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 919.14 Thousand USD | -47.47% |
| 2022 | 1.74 Million USD | 68.08% |
| 2021 | 1.04 Million USD | -18.83% |
| 2020 | 1.28 Million USD | -47.41% |
| 2019 | 2.43 Million USD | 6.81% |
| 2018 | 2.28 Million USD | 41.28% |
| 2017 | 1.61 Million USD | 218.31% |
| 2016 | 507.77 Thousand USD | 25.44% |
| 2015 | 404.79 Thousand USD | 0.0% |
| 2013 | 2.26 USD | 0.0% |
| 2009 | 1.99 Million USD | 3011.17% |
| 2008 | 64.14 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 919.14 Thousand USD | -47.47% |
| 2023 Q3 | 239 Thousand USD | 2.64% |
| 2023 Q2 | 232.84 Thousand USD | -13.63% |
| 2023 Q4 | 177.69 Thousand USD | -25.65% |
| 2023 Q1 | 269.6 Thousand USD | -35.62% |
| 2022 FY | 1.74 Million USD | 68.08% |
| 2022 Q1 | 159.98 Thousand USD | 135.53% |
| 2022 Q4 | 418.76 Thousand USD | -47.43% |
| 2022 Q3 | 796.53 Thousand USD | 112.44% |
| 2022 Q2 | 374.95 Thousand USD | 134.37% |
| 2021 Q4 | -450.21 Thousand USD | -255.08% |
| 2021 FY | 1.04 Million USD | -18.83% |
| 2021 Q1 | 300.83 Thousand USD | 0.0% |
| 2021 Q2 | 251.66 Thousand USD | -16.34% |
| 2021 Q3 | 290.31 Thousand USD | 15.36% |
| 2020 FY | 1.28 Million USD | -47.41% |
| 2019 FY | 2.43 Million USD | 6.81% |
| 2018 FY | 2.28 Million USD | 41.28% |
| 2017 FY | 1.61 Million USD | 218.31% |
| 2016 FY | 507.77 Thousand USD | 25.44% |
| 2015 FY | 404.79 Thousand USD | 0.0% |
| 2013 FY | 2.26 USD | 0.0% |
| 2010 Q3 | 184.77 Thousand USD | -2.46% |
| 2010 Q2 | 189.44 Thousand USD | -15.93% |
| 2010 Q1 | 225.33 Thousand USD | -88.49% |
| 2009 Q1 | 15.66 Thousand USD | 54.37% |
| 2009 Q3 | 6723.00 USD | -57.39% |
| 2009 Q4 | 1.95 Million USD | 29014.99% |
| 2009 Q2 | 15.77 Thousand USD | 0.75% |
| 2009 FY | 1.99 Million USD | 3011.17% |
| 2008 Q4 | 10.14 Thousand USD | -1.2% |
| 2008 Q1 | 34.37 Thousand USD | 0.0% |
| 2008 Q3 | 10.26 Thousand USD | 9.77% |
| 2008 Q2 | 9354.00 USD | -72.79% |
| 2008 FY | 64.14 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 31.173% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 81.77% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.89% |
| Nascent Biotech, Inc. | 2.22 Million USD | 58.781% |
| Rebus Holdings, Inc. | 664 Thousand USD | -38.425% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.533% |
| Qrons Inc. | 643.67 Thousand USD | -42.796% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -135.94% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.4% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -121.225% |
| Skye Bioscience, Inc. | 13.54 Million USD | 93.215% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.941% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 81.31% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -251.185% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.926% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 68.482% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 38.801% |
| Mesoblast Limited | 5.9 Million USD | 84.427% |
| Marizyme, Inc. | 19.23 Million USD | 95.223% |
| Genus plc | 147.7 Million USD | 99.378% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 89.53% |
| Pharming Group N.V. | 225.49 Million USD | 99.592% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 55.135% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 31.486% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 88.978% |
| ContraFect Corporation | 56.88 Million USD | 98.384% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 79.151% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 37.843% |
| IMV Inc. | 37.7 Million USD | 97.563% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 67.06% |
| MultiCell Technologies, Inc. | 567.42 USD | -161886.359% |
| ONE Bio Corp. | 6.44 Million USD | 85.736% |
| Accustem Sciences Inc. | 3.74 Million USD | 75.466% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.931% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -72.784% |
| Q BioMed Inc. | 3.43 Million USD | 73.255% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 96.281% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 65.019% |
| Biomind Labs Inc. | 994.18 Thousand USD | 7.548% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.075% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 47.766% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 86.318% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 50.7% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3776.572% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 94.259% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 49.913% |
| GB Sciences, Inc. | 1.42 Million USD | 35.295% |
| Alpha Cognition Inc. | 9.7 Million USD | 90.53% |
| HST Global, Inc. | 140.9 Thousand USD | -552.305% |
| CSL Limited | 3.44 Billion USD | 99.973% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 18.292% |
| Halberd Corporation | 74.84 Thousand USD | -1128.111% |
| Enzolytics Inc. | 2.17 Million USD | 57.828% |
| Agentix Corp. | 1.37 Million USD | 32.995% |
| Resverlogix Corp. | 12.71 Million USD | 92.769% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 74.823% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.94% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 11.959% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 61.781% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 41.803% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 73.006% |
| AVAX Technologies, Inc. | 7.31 Million USD | 87.427% |
| Zenith Capital Corp. | 8.94 Million USD | 89.722% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.889% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5176.063% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 62.565% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -435.915% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 52.151% |
| Kadimastem Ltd | 2.41 Million USD | 61.863% |
| Helix BioMedix, Inc. | 1.97 Million USD | 53.391% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 91.542% |
| BioStem Technologies, Inc. | 22.97 Million USD | 95.999% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -406.457% |
| LadRx Corporation | 3.81 Million USD | 75.887% |
| Cell Source, Inc. | 4.32 Million USD | 78.75% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 0.473% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 0.473% |
| NovAccess Global Inc. | 2.46 Million USD | 62.739% |
| Affymax, Inc. | 39.38 Million USD | 97.666% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 78.314% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 17.86% |
| Mobile Lads Corp. | 554.54 Thousand USD | -65.747% |
| CytoDyn Inc. | 18.05 Million USD | 94.91% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3551.885% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -317.644% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 35.262% |
| SYBLEU INC | 160.87 Thousand USD | -471.336% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 49.395% |
| International Stem Cell Corporation | 5.27 Million USD | 82.562% |
| Bioxytran, Inc. | 3.82 Million USD | 75.94% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1646.026% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4418.227% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.466% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 43.193% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -24.912% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 70.455% |
| Neutra Corp. | 243.82 Thousand USD | -276.975% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.735% |
| PureTech Health plc | 144.59 Million USD | 99.364% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.514% |
| IXICO plc | 4.7 Million USD | 80.473% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 89.552% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.219% |
| CSL Limited | 3.89 Billion USD | 99.976% |
| Cellectis S.A. | 97.32 Million USD | 99.056% |